<DOC>
	<DOCNO>NCT01621750</DOCNO>
	<brief_summary>To compare bioavailability characterize pharmacokinetic profile Sponsor 's formulation ( Clopidogrel Bisulfate 300 mg Tablets ) respect reference formulation ( Plavix® 300 mg tablet ) healthy , adult , human , male subject fast condition assess bioequivalence .</brief_summary>
	<brief_title>Bioequivalence Study Clopidogrel Tablets 300 mg Under Fasting Conditions</brief_title>
	<detailed_description>An open label , balance , randomize , two treatment , two sequence , two period , single-dose , crossover oral bioequivalence study Clopidogrel Bisulfate 300 mg Tablets Dr. Reddy 's Laboratories Ltd. , India Plavix® ( Clopidogrel Bisulfate ) 300 mg Tablets Bristol-Myers Squibb/Sanofi pharmaceutical partnership Bridgewater , NJ 0880750086441 , USA , healthy , adult , human male subject fasting condition .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Healthy adult human male volunteer 18 55 year age ( inclusive ) live around Ahmedabad city western part India . Having Body Mass Index ( BMI ) 18.5 24.9 ( inclusive ) , calculate weight kg/height m2 . Not significant disease clinically significant abnormal finding screen , medical history , clinical examination , laboratory evaluation , 12lead ECG Xray chest ( posteroanterior view ) recording . Able understand comply study procedure , opinion Principal investigator . Able give voluntary write consent participation trial . Known hypersensitivity idiosyncratic reaction Clopidogrel related drug . History presence disease condition might compromise haemopoietic , renal , hepatic , endocrine , pulmonary , central nervous , cardiovascular , immunological , dermatological , gastrointestinal body system . Ingestion medication time 14 day prior dose PeriodI . In case subject selection discretion Principal Investigator . Any history presence asthma ( include aspirin induce asthma ) nasal polyp NSAID induce urticaria . A recent history alcoholism ( less 2 year ) daily consumption moderate ( 180 mL / day ) alcohol use consumption alcohol within 48 hour prior receive study medicine . The presence clinically significant abnormal laboratory value include APTT PT screen . Consumption grapefruit and/or grapefruit product within 48hrs prior dosing . Use recreational drug history drug addiction test positive prestudy drug scan . History psychiatric disorder . A history difficulty donate blood . Donation blood ( 1 unit 350 mL ) within 90 day prior receive first dose IP . Note : In case blood loss le equal 200 mL ; subject enrol 60 day blood donation . Smokers , smoke 10 cigarette / day inability abstain smoking study . A positive hepatitis screen include hepatitis B surface antigen , HCV antibodies . A positive test result HIV antibody and/or syphilis . The receipt investigational product participation drug research study within period 90 day prior first dose study medication . Elimination halflife study drug take consideration inclusion subject study . Note : If subject participate study blood loss le equal 200 mL , subject dose 60 day last sample previous study . An unusual diet , whatever reason ( e.g . lowsodium ) , four week prior receive study medication throughout subject ' participation study . In case subject selection discretion Principal Investigator . Any history peptic ulcer disease , include gastric &amp; duodenal ulcer bleed disorder .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>